Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction

Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction

US Patent 8895018 · Granted Nov 25, 2014

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Recombinant polypeptides comprising modified MHC class II DRa1 domains and metho2024
Recombinant CD74 polypeptides2020
Methods of treating inflammatory or autoimmune disorders with compounds that bin2020
Recombinant polypeptides comprising MHC class II α1 domains2019
Recombinant polypeptides comprising MHC class II α1 domains2019
Monomeric recombinant MHC molecules useful for manipulation of antigen-specific 2018
Monomeric recombinant MHC molecules useful for manipulation of antigen-specific 2018
Compositions and methods using recombinant MHC molecules for the treatment of st2016
Compositions and methods using recombinant MHC molecules for the treatment of st2016
Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsych2016
Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsych2016
Treatment of retinal disorders with recombinant T cell receptor ligand (RTL)2016